CADLCandel Therapeutics, Inc.
$9.66+72% 1Y
$9.66
$4.4252 weeks$13.76
Price
+72%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, the market undecided.
P/En/a
Market value$707.8M
1 year+72%
5 years-11%
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 10, 2026On September 6, 2026, the Board of Directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) increased the size of the Board from ten (10) to eleven (11) directors and unanimously appointed Martine Zimmermann, Pharm.D, to fill the newly created vacancy on the Board, effective September 8, 2026.Director or officer change · Form 8-K
- Aug 13, 2026Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights.Earnings release · press release
- Jun 16, 2026On June 12, 2026, Candel Therapeutics, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Charles Schoch, the Company’s Chief Financial Officer.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.